dotMD.com
Join Community
📖Formal Study Breakdown Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
Back to Plain-English 8th-Grade Story
Google Scholar NIH PubMed #42934895
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42934895

A Randomized, Double-Blind, Placebo-Controlled Study of the PD-1 Inhibitor Cetrelimab in Chronic Hepatitis B

Journal of viral hepatitis

Verbatim Formal Study Abstract

Published in Journal of viral hepatitis (2026-11-15) • Study Design: Randomized Controlled Trial • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 88/100. Primary Takeaway: There was no change in HBV biomarkers and further development of cetrelimab for HBV was abandoned.